BR112022021766A2 - Materiais e métodos para tratar artrite idiopática juvenil - Google Patents
Materiais e métodos para tratar artrite idiopática juvenilInfo
- Publication number
- BR112022021766A2 BR112022021766A2 BR112022021766A BR112022021766A BR112022021766A2 BR 112022021766 A2 BR112022021766 A2 BR 112022021766A2 BR 112022021766 A BR112022021766 A BR 112022021766A BR 112022021766 A BR112022021766 A BR 112022021766A BR 112022021766 A2 BR112022021766 A2 BR 112022021766A2
- Authority
- BR
- Brazil
- Prior art keywords
- idiopathic arthritis
- juvenile idiopathic
- methods
- materials
- treat juvenile
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Farming Of Fish And Shellfish (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063015894P | 2020-04-27 | 2020-04-27 | |
| US202063015902P | 2020-04-27 | 2020-04-27 | |
| US202063015889P | 2020-04-27 | 2020-04-27 | |
| PCT/IB2021/053429 WO2021220140A1 (en) | 2020-04-27 | 2021-04-26 | Materials and methods for treating juvenile idiopathic arthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022021766A2 true BR112022021766A2 (pt) | 2022-12-13 |
Family
ID=78292529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022021766A BR112022021766A2 (pt) | 2020-04-27 | 2021-04-26 | Materiais e métodos para tratar artrite idiopática juvenil |
Country Status (11)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025034540A1 (en) * | 2023-08-10 | 2025-02-13 | Alexion Pharmaceuticals, Inc. | Immunosuppressive therapy to mitigate anti-soluble alkaline phosphatase immune response |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5757495B2 (ja) * | 2005-05-16 | 2015-07-29 | アッヴィ バイオテクノロジー リミテッド | びらん性多発性関節炎の治療のためのｔｎｆ阻害剤の使用 |
| US10465003B2 (en) * | 2016-02-05 | 2019-11-05 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes |
| CN110234351A (zh) * | 2017-01-30 | 2019-09-13 | 詹森生物科技公司 | 用于治疗活动性银屑病关节炎的抗tnf抗体、组合物和方法 |
-
2021
- 2021-04-26 WO PCT/IB2021/053429 patent/WO2021220140A1/en not_active Ceased
- 2021-04-26 IL IL297623A patent/IL297623A/en unknown
- 2021-04-26 CA CA3127807A patent/CA3127807A1/en active Pending
- 2021-04-26 JP JP2022565551A patent/JP2023524668A/ja active Pending
- 2021-04-26 MX MX2022013502A patent/MX2022013502A/es unknown
- 2021-04-26 US US17/240,609 patent/US20210340245A1/en active Pending
- 2021-04-26 CN CN202180031397.9A patent/CN115461365A/zh active Pending
- 2021-04-26 KR KR1020227041143A patent/KR20230005284A/ko active Pending
- 2021-04-26 AU AU2021263136A patent/AU2021263136A1/en active Pending
- 2021-04-26 BR BR112022021766A patent/BR112022021766A2/pt unknown
- 2021-04-26 EP EP21797784.2A patent/EP4143226A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL297623A (en) | 2022-12-01 |
| US20210340245A1 (en) | 2021-11-04 |
| AU2021263136A1 (en) | 2023-01-05 |
| MX2022013502A (es) | 2023-02-01 |
| EP4143226A4 (en) | 2024-05-29 |
| KR20230005284A (ko) | 2023-01-09 |
| CN115461365A (zh) | 2022-12-09 |
| WO2021220140A1 (en) | 2021-11-04 |
| EP4143226A1 (en) | 2023-03-08 |
| JP2023524668A (ja) | 2023-06-13 |
| CA3127807A1 (en) | 2021-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR075790A2 (es) | Anticuerpos anti -ngf humanos neutralizantes como inhibidores selectivos de la via de ngf (factor de crecimiento neural) | |
| PE20030065A1 (es) | Metodos para administrar anticuerpos anti-tnfalfa | |
| AR083747A1 (es) | Anticuerpos anti-il-23 | |
| BR112018015754A2 (pt) | anticorpos anti-tnf, composições, métodos e uso para o tratamento ou prevenção de diabetes tipo 1 | |
| IL200373A (en) | A monoclonal antibody that binds to 3erbb and a pharmacological preparation that includes the same to inhibit 3erbb signaling in humans | |
| PE20001316A1 (es) | Anticuerpo humanizado especifico para 4-1bb humano y composicion farmaceutica que lo contiene | |
| CO6220978A2 (es) | Anticuerpos dirigidos a proteina-1 quimio-tactica de monocitos (mcp-1)y sus usos | |
| CY1114851T1 (el) | Il-1βητα δεσμευτικα αντισωματα και θραυσματα αυτων | |
| EA202190264A1 (ru) | КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn | |
| ATE477277T1 (de) | Weniger immunogene bindungsmoleküle | |
| CO6251320A2 (es) | Polipeptidos dominios variables de anticuerpos y antagonistas | |
| AR125212A1 (es) | Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de estas | |
| AR060017A1 (es) | Composiciones y metodos de uso para anticuerpos de dickkopf -1 | |
| DE60334141D1 (de) | VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE | |
| NO20063026L (no) | Antistoffer | |
| CO6311001A2 (es) | Composiciones para determinar la actividad de la toxina botulinica in vitro basados en nuevas lineas celulares y nuevos anticuerpos especificosmpara snap - 25(197) y metodos para la determinacion | |
| PE20211708A1 (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anticgrp o anti-cgrp-r | |
| BRPI0820885B8 (pt) | "anticorpo ou fraguimento do mesmo, célula de hibridoma, polinucleotídeo, polipeptídeo compreendendoum domínio de cadeia pesada ou leve de anticorpo, método para detecção de gravidez em um animal bovino, kit e método de purificação de um antígeno principal associado à gravidez (pag)". | |
| MX2022003074A (es) | Anticuerpos anti-cd371, y usos de los mismos. | |
| AR125488A1 (es) | Proteínas de unión biespecíficas de pd-1 y de tigit, y usos de las mismas | |
| MX2017004117A (es) | Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171). | |
| AR073140A1 (es) | Anticuerpos anti-il-23r disenados | |
| PE20232050A1 (es) | Anticuerpos anti-cd19 y estructuras car-t | |
| MX2024001067A (es) | Composicion farmaceutica y uso. | |
| AR118355A1 (es) | Métodos de fabricación para producir composiciones de anticuerpos anti-tnf |